CORT - コ―セプト・セラピュ―ティクス （Corcept Therapeutics Incorporated） コ―セプト・セラピュ―ティクスCORTのチャート
CORTの企業情報
| symbol | CORT |
|---|---|
| 会社名 | Corcept Therapeutics Inc （コ―セプト・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 コーセプト・セラピューティクス（Corcept Therapeutics Incorporated）は重篤な代謝と精神・腫瘍疾患の治療薬の発見・開発・商業化に従事する製薬会社である。同社はグルココルチコイド受容体（GR）においてアンタゴニストとして作用することによりコルチゾールの効果を調節する化合物であるミフェプリストンを開発する。同社は選択的コルチゾールモジュレーターであるCORT125134の2つの臨床試験を実施する。同社はクッシング症候群患者の治療法として、CORT125134を検討する。第2の試験では、固形腫瘍がん患者を治療するためのCORT125134とナブパクリタキセルの組み合わせが検討される。 コ―セプト・セラピュ―ティクスは米国の製薬会社。代謝異常、精神疾患、がん細胞などの治療薬の開発と商品化に従事。主要製品はクッシング病を患う成人の高血糖症治療薬｢Korlym｣。また、心因性うつ病治療薬として｢Korlym｣の有効成分であるミフェプリストンの開発も進める。 Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders. |
| 本社所在地 | 149 Commonwealth Drive Menlo Park CA 94025 USA |
| 代表者氏名 | James N. Wilson ジェームズ・N・ウィルソン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-327-3270 |
| 設立年月日 | 35916 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 1982年 |
| 従業員数 | 136人 |
| url | www.corcept.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cort |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 77.13800 |
| 終値（lastsale） | 13.295 |
| 時価総額（marketcap） | 1542901262.39 |
| 時価総額 | 時価総額（百万ドル） 1591.063 |
| 売上高 | 売上高（百万ドル） 216.01400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1431.118 |
| 当期純利益 | 当期純利益（百万ドル） 180.97500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Corcept Therapeutics Incorporated revenues increased 90% to $120M. Net income increased from $17M to $35.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.15 to $0.31. |
CORTのテクニカル分析
CORTのニュース
Corcept Therapeutics Incorporated (CORT) Q1 2023 Earnings Call Transcript 2023/05/04 03:43:04 Seeking Alpha
Corcept Therapeutics Incorporated (NASDAQ:NASDAQ:CORT) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ETCompany ParticipantsAtabak Mokari - Chief Financial OfficerCharlie Robb - Chief…
Corcept Therapeutics GAAP EPS of $0.14 misses by $0.05, revenue of $105.7M beats by $0.79M 2023/05/03 20:15:53 Seeking Alpha
Corcept Therapeutics press release (CORT): Q1 GAAP EPS of $0.14 misses by $0.05.Revenue of $105.7M (+12.8% Y/Y) beats by $0.79M.Cash and investments of $465.1 million as of March…
Piper Sandler Starts Corcept Therapeutics at Overweight 2023/04/04 06:44:01 Investing.com
https://www.investing.com/news/pro/piper-sandler-starts-corcept-therapeutics-at-overweight-432SI-3048277
Corcept Therapeutics Initiates CATALYST Trial 2023/03/28 20:08:01 Investing.com
https://www.investing.com/news/assorted/corcept-therapeutics-initiates-catalyst-trial-432SI-3043015
Corcept Therapeutics Initiates CATALYST Clinical Trial 2023/03/28 20:05:00 GlobeNewswire
MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has initiated CATALYST, a 1,000-patient, Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult to control type 2 diabetes. Those patients with hypercortisolism will be offered entry into a randomized, double-blind, placebo-controlled study of Korlym ® .
Corcept Therapeutics Incorporated (CORT) Q3 2022 Earnings Call Transcript | AlphaStreet 2022/11/04 19:04:21 AlphaStreet
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2022 Earnings Call dated Nov. 03, 2022.
Corcept Therapeutics Incorporated (CORT) Q3 2022 Earnings Call Transcript 2022/11/04 03:11:04 Seeking Alpha
Corcept Therapeutics Incorporated (NASDAQ:NASDAQ:CORT) Q3 2022 Earnings Conference Call November 03, 2022 05:00 PM ET Company Participants Joseph Belanoff - CEO and President Atabak Mokari…
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update 2022/11/03 20:05:00 GlobeNewswire
MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2022.
Corcept Therapeutics''s Earnings: A Preview 2022/11/02 18:39:16 Benzinga
Corcept Therapeutics (NASDAQ: CORT ) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here''s what investors need to know before the announcement. Analysts estimate that Corcept Therapeutics will report an earnings per share (EPS) of $0.22. Corcept Therapeutics bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call 2022/10/27 20:05:00 GlobeNewswire
MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer 2022/06/29 21:21:37 Seeking Alpha
Corcept Therapeutics (CORT) has commenced a phase 3 study of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
After A 20% Rally This Month, Here''s Why This Biotech Is Worth Considering 2022/06/27 19:48:56 Investor''s Business Daily
Biotech stocks like Corcept Therapeutics are worth considering for your portfolio as shares near a proper buy point amid a powerful rally.
Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Novartis, and Corcept and Encourages Investors to Contact the Firm 2022/06/09 01:00:00 GlobeNewswire
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), Novartis AG (NYSE: NVS), and Corcept Therapeutics, Inc. (NASDAQ: CORT). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.